NCT04406571: CAPANCOVID-19

Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer

Completed Last updated 24 January 2024

What this trial tests

trial testing Data record in Pancreatic Adenocarcinoma in 700 participants. Completed in 31 May 2022.

Timeline

1 April 2020

Primary endpoint
31 December 2021

31 May 2022

Quick facts

Lead sponsor	CHU de Reims
Status	Completed
Study type	OBSERVATIONAL
Enrollment	700
Start date	1 April 2020
Primary completion	31 December 2021
Estimated completion	31 May 2022
Sites	1 location across France

Drugs / interventions tested

• Data record

Conditions studied

• Pancreatic Adenocarcinoma — all drugs for Pancreatic Adenocarcinoma →

Sponsor

CHU de Reims — full company profile →

Who can join

18 and older, any sex, with Pancreatic Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pancreatic adenocarcinoma will be the 2nd cause of death by cancer in Europe in 2030. Pancreatic adenocarcinoma has poor prognosis with an all-stages combined 5-year survival rate below 8%.

Since December 2019, a new coronavirus (Severe Acute Respiratory Syndrome Corona Virus 2, SARS-CoV-2) is responsible of COVID-19 infection with potentially severe respiratory syndrome or even multi-organ failure. An increased risk of severe COVID-19 infection in cancer patients is suggested in several Chinese series. Cancer care structures quickly reorganized to limit high-risk situations (diagnostic procedure, major surgery, cytotoxic poly-chemotherapy) and use alternatives such as on-hold chemotherapy. These reorganizations could be associated with a loss of chance for pancreatic adenocarcinoma.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
   Vivarelli S, Falzone L, Grillo CM, Scandurra G, et al · · 2020 · cited 63× · PMID 32785162 · DOI 10.3390/cancers12082237
2. Dramatic Changes in Oncology Care Pathways During the COVID-19 Pandemic: The French ONCOCARE-COV Study.
   Brugel M, Carlier C, Essner C, Debreuve-Theresette A, et al · · 2021 · cited 40× · PMID 33111460 · DOI 10.1002/onco.13578
3. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective observational cohort study (CAPANCOVID).
   Brugel M, Letrillart L, Evrard C, Thierry A, et al · · 2022 · cited 22× · PMID 35259629 · DOI 10.1016/j.ejca.2022.01.040
4. One-year COVID-19 outcomes on the oncology care patient pathway: Results of a French descriptive, cross-sectional comprehensive study (ONCOCARE-COV).
   Laurent L, Brugel M, Carlier C, Clere F, et al · · 2022 · cited 5× · PMID 35593199 · DOI 10.1002/cam4.4817
5. Time from first seen in specialist care to surgery does not influence survival outcome in patients with upfront resected pancreatic adenocarcinoma.
   Brugel M, Bouché O, Kianmanesh R, Teuma L, et al · · 2021 · cited 4× · PMID 34876080 · DOI 10.1186/s12893-021-01409-7
6. Molecular analysis in pancreatic adenocarcinoma: a real-world study from high-volume French centres (CAPANCOBIO study).
   Evrard C, Brugel M, Piessen G, Roth G, et al · · 2025 · PMID 41646475 · DOI 10.1016/j.esmogo.2025.100142